Healthcare provider profile · identity verified

Sujit Ram Varma, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · EDINA, MN · NPI 1013018258

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Sujit Ram Varma, MD received $155,087.28 in general payments during 2025 across 236 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 49.7% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 23 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Auvelity, Caplyta, Fanapt, Loreev Xr, Lybalvi, Quviviq, Rexulti, Sunosi, Trintellix, Wakix, Xywav.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Lybalvi by this doctor in 2024.

Almatica Pharma LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOREEV XR as an associated drug or biological on 9621 records involving 4446 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Loreev Xr by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Auvelity by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Sunosi as an associated drug or biological on 19758 records involving 6305 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Sunosi by this doctor in 2024.

HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Wakix by this doctor in 2024.

IDORSIA PHARMACEUTICALS US INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QUVIVIQ as an associated drug or biological on 2281 records involving 1911 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Quviviq by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Caplyta by this doctor in 2024.

JAZZ PHARMACEUTICALS INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XYWAV as an associated drug or biological on 19511 records involving 5343 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Xywav by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Austedo Xr by this doctor in 2024.

Vanda Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FANAPT as an associated drug or biological on 95605 records involving 21383 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Fanapt by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$155,087.28

236 reported records · 16 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$77,137.79	49.7%	104	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$31,513.83	20.3%	27	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$14,896.66	9.6%	23	2025
HARMONY BIOSCIENCES LLC	Unresolved — no canonical attribution shown	$14,016.28	9.0%	18	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$7,410.09	4.8%	17	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$5,205.76	3.4%	13	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$4,453.96	2.9%	15	2025
LivaNova USA, Inc.	Unresolved — no canonical attribution shown	$148.70	0.1%	1	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$145.73	0.1%	10	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$51.61	0.0%	2	2025
IDORSIA PHARMACEUTICALS US INC	Unresolved — no canonical attribution shown	$23.88	0.0%	1	2025
JAZZ PHARMACEUTICALS INC.	Unresolved — no canonical attribution shown	$17.34	0.0%	1	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$17.04	0.0%	1	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$16.71	0.0%	1	2025
Almatica Pharma LLC	Unresolved — no canonical attribution shown	$16.13	0.0%	1	2025
Tris Pharma Inc	Unresolved — no canonical attribution shown	$15.77	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$113,986.00	39
Travel and Lodging	$16,556.38	92
Honoraria	$13,750.00	3
Consulting Fee	$8,103.00	8
Food and Beverage	$2,680.03	93
Education	$11.87	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$77,137.79	104	2025
Source payment records 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.75 · Open Payments source 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,780.00 · Open Payments source 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $556.96 · Open Payments source 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $191.73 · Open Payments source 2025-01-08 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $293.54 · Open Payments source 2025-01-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.34 · Open Payments source 2025-01-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,680.00 · Open Payments source 2025-01-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.00 · Open Payments source 2025-01-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.62 · Open Payments source 2025-01-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.36 · Open Payments source 2025-01-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,780.00 · Open Payments source 2025-01-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $40.00 · Open Payments source 2025-01-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $110.80 · Open Payments source 2025-01-28 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.80 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.23 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,780.00 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $536.96 · Open Payments source 2025-02-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $319.43 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $125.00 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,200.00 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $506.96 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $163.89 · Open Payments source 2025-02-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $142.81 · Open Payments source 2025-03-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,260.00 · Open Payments source 2025-03-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.83 · Open Payments source 2025-03-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,940.00 · Open Payments source 2025-03-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $40.00 · Open Payments source 2025-03-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $166.60 · Open Payments source 2025-03-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $476.97 · Open Payments source 2025-04-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.24 · Open Payments source 2025-06-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.52 · Open Payments source 2025-07-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.23 · Open Payments source 2025-07-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $536.97 · Open Payments source 2025-07-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $68.92 · Open Payments source 2025-07-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.67 · Open Payments source 2025-07-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.40 · Open Payments source 2025-07-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-08-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $9.37 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $138.53 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $230.00 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $24.29 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $275.45 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $46.64 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $52.94 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.09 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.43 · Open Payments source 2025-10-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $92.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $331.97 · Open Payments source 2025-10-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $8.64 · Open Payments source 2025-10-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.36 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,128.09 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.48 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $116.49 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.28 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.30 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $6.30 · Open Payments source 2025-10-31 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $88.99 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.00 · Open Payments source 2025-11-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $73.29 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $120.33 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $7.40 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.82 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.95 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $64.99 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-11-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.03 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $150.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $149.00 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $11.20 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.94 · Open Payments source 2025-11-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $287.54 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $72.71 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.68 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $168.00 · Open Payments source 2025-11-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.20 · Open Payments source 2025-12-01 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,080.00 · Open Payments source 2025-12-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $115.43 · Open Payments source 2025-12-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $526.97 · Open Payments source 2025-12-02 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $154.48 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.52 · Open Payments source 2025-12-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $197.10 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $51.98 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $378.20 · Open Payments source 2025-12-10 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $196.87 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3.49 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $67.31 · Open Payments source 2025-12-15 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $59.69 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,520.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $139.90 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.56 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $182.99 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $36.11 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $62.94 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $69.01 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,960.00 · Open Payments source 2025-12-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source 2025-12-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,400.00 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$18,734.98	19	2025
Source payment records 2025-01-23 · Teva Pharmaceuticals USA, Inc. · $22.40 · Open Payments source 2025-01-23 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-02-06 · Teva Pharmaceuticals USA, Inc. · $2.10 · Open Payments source 2025-02-06 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-02-20 · Teva Pharmaceuticals USA, Inc. · $151.06 · Open Payments source 2025-04-09 · Teva Pharmaceuticals USA, Inc. · $3.50 · Open Payments source 2025-04-09 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-04-22 · Teva Pharmaceuticals USA, Inc. · $3,570.00 · Open Payments source 2025-04-22 · Teva Pharmaceuticals USA, Inc. · $121.14 · Open Payments source 2025-07-22 · Teva Pharmaceuticals USA, Inc. · $14.39 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $10.00 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $119.65 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $196.81 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $810.90 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $4,046.00 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $65.62 · Open Payments source 2025-07-23 · Teva Pharmaceuticals USA, Inc. · $97.41 · Open Payments source 2025-07-24 · Teva Pharmaceuticals USA, Inc. · $1,904.00 · Open Payments source 2025-08-25 · Teva Pharmaceuticals USA, Inc. · $460.00 · Open Payments source
Sunosi Normalized: sunosi	Drug	Axsome Therapeutics, Inc.	$14,874.11	20	2025
Source payment records 2025-02-12 · Axsome Therapeutics, Inc. · $1.71 · Open Payments source 2025-02-12 · Axsome Therapeutics, Inc. · $2.75 · Open Payments source 2025-04-11 · Axsome Therapeutics, Inc. · $1,650.00 · Open Payments source 2025-04-11 · Axsome Therapeutics, Inc. · $21.00 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $43.33 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $62.50 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $56.68 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $9.28 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $18.33 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $18.33 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $382.96 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $204.06 · Open Payments source 2025-05-03 · Axsome Therapeutics, Inc. · $22.65 · Open Payments source 2025-05-16 · Axsome Therapeutics, Inc. · $2,750.00 · Open Payments source 2025-05-16 · Axsome Therapeutics, Inc. · $175.00 · Open Payments source 2025-05-30 · Axsome Therapeutics, Inc. · $72.71 · Open Payments source 2025-05-30 · Axsome Therapeutics, Inc. · $16.80 · Open Payments source 2025-06-17 · Axsome Therapeutics, Inc. · $9,350.00 · Open Payments source 2025-11-11 · Axsome Therapeutics, Inc. · $7.29 · Open Payments source 2025-12-17 · Axsome Therapeutics, Inc. · $8.73 · Open Payments source
WAKIX Normalized: wakix	Drug	HARMONY BIOSCIENCES LLC	$14,016.28	18	2025
Source payment records 2025-02-14 · HARMONY BIOSCIENCES LLC · $381.00 · Open Payments source 2025-02-19 · HARMONY BIOSCIENCES LLC · $762.00 · Open Payments source 2025-02-19 · HARMONY BIOSCIENCES LLC · $48.19 · Open Payments source 2025-06-17 · HARMONY BIOSCIENCES LLC · $1,143.00 · Open Payments source 2025-06-18 · HARMONY BIOSCIENCES LLC · $220.86 · Open Payments source 2025-06-18 · HARMONY BIOSCIENCES LLC · $3,486.00 · Open Payments source 2025-06-18 · HARMONY BIOSCIENCES LLC · $90.91 · Open Payments source 2025-06-18 · HARMONY BIOSCIENCES LLC · $78.34 · Open Payments source 2025-06-18 · HARMONY BIOSCIENCES LLC · $145.17 · Open Payments source 2025-06-18 · HARMONY BIOSCIENCES LLC · $836.98 · Open Payments source 2025-06-23 · HARMONY BIOSCIENCES LLC · $38.97 · Open Payments source 2025-06-23 · HARMONY BIOSCIENCES LLC · $165.39 · Open Payments source 2025-06-23 · HARMONY BIOSCIENCES LLC · $3,486.00 · Open Payments source 2025-06-23 · HARMONY BIOSCIENCES LLC · $696.97 · Open Payments source 2025-06-23 · HARMONY BIOSCIENCES LLC · $110.79 · Open Payments source 2025-08-19 · HARMONY BIOSCIENCES LLC · $136.71 · Open Payments source 2025-08-19 · HARMONY BIOSCIENCES LLC · $65.00 · Open Payments source 2025-08-19 · HARMONY BIOSCIENCES LLC · $2,124.00 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$12,778.85	8	2025
Source payment records 2025-01-16 · Teva Pharmaceuticals USA, Inc. · $7.38 · Open Payments source 2025-03-13 · Teva Pharmaceuticals USA, Inc. · $1.96 · Open Payments source 2025-03-13 · Teva Pharmaceuticals USA, Inc. · $166.60 · Open Payments source 2025-03-13 · Teva Pharmaceuticals USA, Inc. · $198.91 · Open Payments source 2025-03-13 · Teva Pharmaceuticals USA, Inc. · $1,904.00 · Open Payments source 2025-03-13 · Teva Pharmaceuticals USA, Inc. · $3,570.00 · Open Payments source 2025-03-30 · Teva Pharmaceuticals USA, Inc. · $6,510.00 · Open Payments source 2025-11-30 · Teva Pharmaceuticals USA, Inc. · $420.00 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$7,401.41	15	2025
Source payment records 2025-01-15 · Alkermes, Inc. · $4.29 · Open Payments source 2025-02-12 · Alkermes, Inc. · $8.05 · Open Payments source 2025-02-13 · Alkermes, Inc. · $10.49 · Open Payments source 2025-02-27 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-03-20 · Alkermes, Inc. · $5.62 · Open Payments source 2025-05-07 · Alkermes, Inc. · $4.89 · Open Payments source 2025-05-13 · Alkermes, Inc. · $800.00 · Open Payments source 2025-05-23 · Alkermes, Inc. · $5.33 · Open Payments source 2025-06-25 · Alkermes, Inc. · $4.94 · Open Payments source 2025-07-25 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-07-31 · Alkermes, Inc. · $2.80 · Open Payments source 2025-08-15 · Alkermes, Inc. · $1,910.00 · Open Payments source 2025-08-15 · Alkermes, Inc. · $800.00 · Open Payments source 2025-08-22 · Alkermes, Inc. · $19.60 · Open Payments source 2025-09-17 · Alkermes, Inc. · $5.40 · Open Payments source
REXULTI Normalized: rexulti	Drug	Otsuka America Pharmaceutical, Inc.	$5,181.61	8	2025
Source payment records 2025-01-22 · Otsuka America Pharmaceutical, Inc. · $5.13 · Open Payments source 2025-03-26 · Otsuka America Pharmaceutical, Inc. · $3.83 · Open Payments source 2025-04-18 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-30 · Otsuka America Pharmaceutical, Inc. · $2,106.00 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $23.80 · Open Payments source 2025-09-10 · Otsuka America Pharmaceutical, Inc. · $4.23 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $581.62 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $2,106.00 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$3,073.96	13	2025
Source payment records 2025-01-14 · E.R. Squibb & Sons, L.L.C. · $12.05 · Open Payments source 2025-02-11 · E.R. Squibb & Sons, L.L.C. · $6.89 · Open Payments source 2025-04-07 · E.R. Squibb & Sons, L.L.C. · $1,610.00 · Open Payments source 2025-04-30 · E.R. Squibb & Sons, L.L.C. · $6.30 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $49.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $647.68 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $64.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 · Open Payments source 2025-11-10 · E.R. Squibb & Sons, L.L.C. · $103.27 · Open Payments source
VNS THERAPY SYMMETRY MODEL 8103 GENERATOR Normalized: vns therapy symmetry model 8103 generator	Device	LivaNova USA, Inc.	$148.70	1	2025
Source payment records 2025-03-25 · LivaNova USA, Inc. · $148.70 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$145.73	10	2025
Source payment records 2025-02-20 · Vanda Pharmaceuticals Inc. · $16.92 · Open Payments source 2025-03-20 · Vanda Pharmaceuticals Inc. · $6.55 · Open Payments source 2025-04-17 · Vanda Pharmaceuticals Inc. · $12.26 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $23.99 · Open Payments source 2025-04-23 · Vanda Pharmaceuticals Inc. · $11.87 · Open Payments source 2025-05-15 · Vanda Pharmaceuticals Inc. · $6.16 · Open Payments source 2025-07-30 · Vanda Pharmaceuticals Inc. · $29.08 · Open Payments source 2025-09-16 · Vanda Pharmaceuticals Inc. · $10.61 · Open Payments source 2025-10-08 · Vanda Pharmaceuticals Inc. · $13.86 · Open Payments source 2025-11-19 · Vanda Pharmaceuticals Inc. · $14.43 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$51.61	2	2025
Source payment records 2025-11-18 · Supernus Pharmaceuticals, Inc. · $24.61 · Open Payments source 2025-11-18 · Supernus Pharmaceuticals, Inc. · $27.00 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$44.52	8	2025
Source payment records 2025-01-15 · Alkermes, Inc. · $4.29 · Open Payments source 2025-02-12 · Alkermes, Inc. · $8.05 · Open Payments source 2025-03-20 · Alkermes, Inc. · $5.62 · Open Payments source 2025-05-07 · Alkermes, Inc. · $4.89 · Open Payments source 2025-05-23 · Alkermes, Inc. · $5.33 · Open Payments source 2025-06-03 · Alkermes, Inc. · $6.00 · Open Payments source 2025-06-25 · Alkermes, Inc. · $4.94 · Open Payments source 2025-09-17 · Alkermes, Inc. · $5.40 · Open Payments source
Quviviq Normalized: quviviq	Drug	IDORSIA PHARMACEUTICALS US INC	$23.88	1	2025
Source payment records 2025-04-11 · IDORSIA PHARMACEUTICALS US INC · $23.88 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$22.55	3	2025
Source payment records 2025-05-30 · Axsome Therapeutics, Inc. · $5.97 · Open Payments source 2025-07-08 · Axsome Therapeutics, Inc. · $10.14 · Open Payments source 2025-10-24 · Axsome Therapeutics, Inc. · $6.44 · Open Payments source
XYWAV Normalized: xywav	Drug	JAZZ PHARMACEUTICALS INC.	$17.34	1	2025
Source payment records 2025-07-08 · JAZZ PHARMACEUTICALS INC. · $17.34 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$17.04	1	2025
Source payment records 2025-09-02 · Takeda Pharmaceuticals U.S.A., Inc. · $17.04 · Open Payments source
Belbuca Normalized: belbuca	Drug	Collegium Pharmaceutical, Inc.	$16.71	1	2025
Source payment records 2025-02-18 · Collegium Pharmaceutical, Inc. · $16.71 · Open Payments source
LOREEV XR Normalized: loreev xr	Drug	Almatica Pharma LLC	$16.13	1	2025
Source payment records 2025-06-24 · Almatica Pharma LLC · $16.13 · Open Payments source
Onyda XR Normalized: onyda xr	Drug	Tris Pharma Inc	$15.77	1	2025
Source payment records 2025-04-17 · Tris Pharma Inc · $15.77 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$14.11	2	2025
Source payment records 2025-02-14 · Otsuka America Pharmaceutical, Inc. · $4.97 · Open Payments source 2025-04-09 · Otsuka America Pharmaceutical, Inc. · $9.14 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$10.04	3	2025
Source payment records 2025-07-30 · Otsuka America Pharmaceutical, Inc. · $0.39 · Open Payments source 2025-07-31 · Otsuka America Pharmaceutical, Inc. · $2.00 · Open Payments source 2025-10-01 · Otsuka America Pharmaceutical, Inc. · $7.65 · Open Payments source
ARISTADA INITIO Normalized: aristada initio	Drug	Alkermes, Inc.	$6.00	1	2025
Source payment records 2025-06-03 · Alkermes, Inc. · $6.00 · Open Payments source
VIVITROL Normalized: vivitrol	Drug	Alkermes, Inc.	$2.68	1	2025
Source payment records 2025-11-12 · Alkermes, Inc. · $2.68 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
AUSTEDO XR austedo xr	2025	Austedo Xr	2024	18 Beneficiary count suppressed	exact normalized	Medicare Part D
Auvelity auvelity	2025	Auvelity	2024	23 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	26 Beneficiary count suppressed	exact normalized	Medicare Part D
FANAPT fanapt	2025	Fanapt	2024	11 Beneficiary count suppressed	exact normalized	Medicare Part D
LOREEV XR loreev xr	2025	Loreev Xr	2024	37 Beneficiary count suppressed	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	27 Beneficiary count suppressed	exact normalized	Medicare Part D
Quviviq quviviq	2025	Quviviq	2024	14 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	21 Beneficiary count suppressed	exact normalized	Medicare Part D
Sunosi sunosi	2025	Sunosi	2024	47 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	93	exact normalized	Medicare Part D
WAKIX wakix	2025	Wakix	2024	42 Beneficiary count suppressed	exact normalized	Medicare Part D
XYWAV xywav	2025	Xywav	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	27	suppressed by CMS
Almatica Pharma LLC Exact reporting entity; no affiliate inference	2025	LOREEV XR open payments reported associated product	CMS Open Payments — General Payments 9621 supporting records · 4446 recipient NPIs · example record 1209929018	Loreev Xr · 2024 Exact normalized brand match · 1 Part D row	37	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	23	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Sunosi open payments reported associated product	CMS Open Payments — General Payments 19758 supporting records · 6305 recipient NPIs · example record 1235293059	Sunosi · 2024 Exact normalized brand match · 1 Part D row	47	suppressed by CMS
HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference	2025	WAKIX open payments reported associated product	CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076	Wakix · 2024 Exact normalized brand match · 1 Part D row	42	suppressed by CMS
IDORSIA PHARMACEUTICALS US INC Exact reporting entity; no affiliate inference	2025	QUVIVIQ open payments reported associated product	CMS Open Payments — General Payments 2281 supporting records · 1911 recipient NPIs · example record 1243392023	Quviviq · 2024 Exact normalized brand match · 1 Part D row	14	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	26	suppressed by CMS
JAZZ PHARMACEUTICALS INC. Exact reporting entity; no affiliate inference	2025	XYWAV open payments reported associated product	CMS Open Payments — General Payments 19511 supporting records · 5343 recipient NPIs · example record 1234297700	Xywav · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	21	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	93	13
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO XR open payments reported associated product	CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228	Austedo Xr · 2024 Exact normalized brand match · 1 Part D row	18	suppressed by CMS
Vanda Pharmaceuticals Inc. Exact reporting entity; no affiliate inference	2025	FANAPT open payments reported associated product	CMS Open Payments — General Payments 95605 supporting records · 21383 recipient NPIs · example record 1232940535	Fanapt · 2024 Exact normalized brand match · 1 Part D row	11	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Clonazepam	Clonazepam	311	40
Duloxetine Hcl	Duloxetine Hcl	168	32
Lorazepam	Lorazepam	156	23
Quetiapine Fumarate	Quetiapine Fumarate	152	28
Trazodone Hcl	Trazodone Hcl	150	39
Gabapentin	Gabapentin	133	22
Zolpidem Tartrate	Zolpidem Tartrate	127	17
Escitalopram Oxalate	Escitalopram Oxalate	123	24
Alprazolam	Alprazolam	115	19
Lamotrigine	Lamotrigine	106	26
Prazosin Hcl	Prazosin Hcl	100	18
Trintellix	Vortioxetine Hydrobromide	93	13
Diazepam	Diazepam	89	12
Sertraline Hcl	Sertraline Hcl	85	17
Buspirone Hcl	Buspirone Hcl	82	11
Spravato	Esketamine Hcl	70	11
Bupropion Xl	Bupropion Hcl	62	17
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	60	14
Lurasidone Hcl	Lurasidone Hcl	57	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	54	15
Fluoxetine Hcl	Fluoxetine Hcl	52	11
Venlafaxine Hcl Er	Venlafaxine Hcl	50	suppressed
Sunosi	Solriamfetol Hcl	47	suppressed
Mirtazapine	Mirtazapine	43	suppressed
Wakix	Pitolisant Hcl	42	suppressed
Loreev Xr	Lorazepam	37	suppressed
Topiramate	Topiramate	37	suppressed
Fetzima	Levomilnacipran Hcl	36	suppressed
Ziprasidone Hcl	Ziprasidone Hcl	34	suppressed
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	32	suppressed
Clonidine Hcl	Clonidine Hcl	30	suppressed
Buprenorphine-Naloxone	Buprenorphine Hcl/Naloxone Hcl	29	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	28	suppressed
Armodafinil	Armodafinil	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	suppressed
Propranolol Hcl	Propranolol Hcl	28	suppressed
Lybalvi	Olanzapine/Samidorphan Malate	27	suppressed
Caplyta	Lumateperone Tosylate	26	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	26	suppressed
Vraylar	Cariprazine Hcl	25	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	24	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	24	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	23	suppressed
Divalproex Sodium Er	Divalproex Sodium	23	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	23	suppressed
Vilazodone Hcl	Vilazodone Hcl	23	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	22	suppressed
Paroxetine Hcl	Paroxetine Hcl	21	suppressed
Rexulti	Brexpiprazole	21	suppressed
Temazepam	Temazepam	21	suppressed
Dayvigo	Lemborexant	20	suppressed
Lamotrigine Er	Lamotrigine	20	suppressed
Aripiprazole	Aripiprazole	19	suppressed
Austedo Xr	Deutetrabenazine	18	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	17	suppressed
Olanzapine	Olanzapine	16	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	15	suppressed
Risperidone	Risperidone	15	suppressed
Lisdexamfetamine Dimesylate	Lisdexamfetamine Dimesylate	14	suppressed
Quviviq	Daridorexant Hcl	14	suppressed
Dexmethylphenidate Hcl Er	Dexmethylphenidate Hcl	12	suppressed
Xywav	Sodium,calcium,mag,pot Oxybate	12	suppressed
Fanapt	Iloperidone	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$155,087.28 · 236 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, Belbuca, CAPLYTA, COBENFY, FANAPT, LOREEV XR, LYBALVI, Onyda XR, Qelbree, Quviviq, REXULTI, Sunosi, TRINTELLIX, UZEDY, VIVITROL, VNS THERAPY SYMMETRY MODEL 8103 GENERATOR, WAKIX, XYWAV	12	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Austedo Xr play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Alkermes, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error